Physician profile
Shadi Eid Mohammad Hamdan
NPI 1801088992
$5,410.58
in general payments reported to CMS, 2019-2025
50 companies · $2,000 in 2025
The $2,000 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $55.66 · 2021: $32.41 · 2022: $645 · 2023: $1,054 · 2024: $1,623 · 2025: $2,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,385 · Education: $293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,384.82 |
| Education | $293.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $532.18 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Astellas Pharma US INC | $367.28 | 2022-2025 | Padcev, Xtandi, Vyloy |
| Pfizer INC. | $288.73 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $281.30 | 2021-2025 | Enhertu, Lynparza, Imfinzi |
| Celgene Corporation | $272.96 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $270.52 | 2023-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Alexion Pharmaceuticals, INC. | $208.77 | 2024-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $205.15 | 2023-2025 | |
| Gilead Sciences, INC. | $205.13 | 2021-2025 | Trodelvy |
| Genentech USA, INC. | $202.02 | 2023-2025 | Polivy, Lunsumio, Tecentriq Hybreza |
| Abbvie INC. | $175.49 | 2023-2025 | |
| Janssen Biotech, INC. | $168.41 | 2023-2025 | Erleada, Rybrevant, Balversa |
| E.R. Squibb & Sons, L.L.C. | $153.22 | 2023-2025 | Opdivo, Opdualag, Eliquis |
| Inspire Medical Systems, INC. | $143.45 | 2025 | Inspire |
| Sobi, INC | $136.34 | 2024-2025 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $134.53 | 2022-2025 | Enhertu |
| Lilly USA, LLC | $118.55 | 2022-2025 | Verzenio, Jaypirca |
| Glaxosmithkline, LLC. | $110.42 | 2022-2025 | Ojjaara, Jemperli, Zejula |
| Ipsen Biopharmaceuticals, INC | $94.03 | 2022-2024 | Tazverik, Onivyde |
| Intuitive Surgical, INC. | $76.79 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $73.19 | 2022-2025 | |
| Emd Serono, INC. | $71.09 | 2024-2025 | |
| Rigel Pharmaceuticals, INC. | $70.70 | 2022 | |
| Incyte Corporation | $69.29 | 2022-2025 | Jakafi |
| Puma Biotechnology, INC. | $68.31 | 2023-2025 | |
| Seagen INC. | $65.80 | 2022-2023 | Padcev, Tukysa |
| Tersera Therapeutics LLC | $64.60 | 2024-2025 | Zoladex |
| Janssen Pharmaceuticals, INC | $62.69 | 2022 | |
| G1 Therapeutics, INC. | $61.02 | 2022-2023 | Cosela |
| Array Biopharma INC | $59.51 | 2025 | Braftovi, Lorbrena, Mektovi |
| Abiomed | $55.66 | 2020 | |
| Myriad Genetic Laboratories, INC. | $46.45 | 2023 | Myrisk |
| Blueprint Medicines Corporation | $45.21 | 2024-2025 | Ayvakit |
| Tempus Ai, INC | $45.17 | 2024 | |
| Mirati Therapeutics, INC. | $40.27 | 2024 | Krazati |
| Genzyme Corporation | $38.08 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $38.03 | 2023 | Zepzelca |
| Melinta Therapeutics, LLC | $31.98 | 2025 | Orbactiv, Kimyrsa, Rezzayo |
| Eisai INC. | $29.47 | 2024 | |
| Azurity Pharmaceuticals, INC. | $25.21 | 2024 | Vivimusta |
| Pharmacosmos Therapeutics INC. | $24.46 | 2024 | Cosela |
| Exelixis INC. | $23.75 | 2022 | |
| Coherus Oncology, INC. | $23.66 | 2024 | |
| Telix Pharmaceuticals | $23.05 | 2024 | Illuccix |
| Amgen INC. | $21.76 | 2023 | Lumakras |
| Pharmacyclics LLC, An Abbvie Company | $20.78 | 2023 | Epkinly, Imbruvica |
| Servier Pharmaceuticals LLC | $19.50 | 2025 | |
| Btg International INC. | $18.20 | 2024 | |
| Kite Pharma, INC. | $14.53 | 2023 | Yescarta |
| Novocure INC. | $13.89 | 2024 | Optune Lua (Novottf-200t) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shadi Hamdan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.